A phase 2 trial, evaluating the activity and the efficacy of trametinib in patients with advanced melanoma not mutated in V600 BRAF (NCT02296112), could help to shed some light on the role of MEK inhibitors in this rare subset of melanoma. Here, MAP2K7 is linked to melanoma.